Desmopressin

證據等級: L5

預測適應症: 7 個

Desmopressin: From Diabetes Insipidus to Inherited Platelet Release Disorders

Multi-Indication Report — This evaluation covers 7 TxGNN-predicted indications for Desmopressin (DB00035). Recommendations differ substantially across predictions; please read each indication section carefully.

One-Sentence Summary

Desmopressin (DDAVP) is a synthetic vasopressin analogue with well-established clinical roles in central diabetes insipidus, nocturnal enuresis, and hemostatic management of mild hemophilia A and von Willebrand disease type 1.

The TxGNN model predicts potential utility across 7 rare inherited bleeding and coagulation disorders, with the strongest actionable signal for primary release disorder of platelets (Evidence Level L3, 15 publications including a 2023 systematic review) and additional research interest for Glanzmann thrombasthenia (L3, 20 publications).

Of the remaining 5 predictions, 4 are Hold due to mechanistic mismatches or insufficient evidence, and 1 carries an active safety warning — Desmopressin is likely contraindicated in pseudo-von Willebrand disease, where its release of high-molecular-weight vWF multimers may paradoxically worsen platelet consumption.

Quick Overview

Drug Information

Item	Content
Drug (INN)	Desmopressin (DDAVP)
DrugBank ID	DB00035
Known Clinical Uses	Central diabetes insipidus, nocturnal enuresis, mild hemophilia A, von Willebrand disease type 1 (hemostatic)
Philippines Market Status	Not marketed
Number of Philippines Registrations	0

TxGNN Prediction Summary — All 7 Indications

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Congenital prothrombin deficiency	99.70%	L4	Hold
2	Inherited thrombophilia	99.44%	L4	Hold — Safety Concern
3	Glanzmann thrombasthenia	99.30%	L3	Research Question
4	Primary release disorder of platelets	99.26%	L3	Proceed with Guardrails
5	Pseudo-von Willebrand disease	99.16%	L4	Hold — Potential Contraindication
6	Scott syndrome	99.16%	L5	Hold
7	Flood factor deficiency	99.15%	L4	Hold — Unclear Disease Entity

Why is This Prediction Reasonable?

Desmopressin is a selective agonist of the V2 receptor (AVPR2) expressed on vascular endothelial cells. Binding triggers rapid exocytosis of Weibel-Palade bodies, releasing stored von Willebrand factor (vWF) — particularly ultra-large, high-molecular-weight (HMW) multimers — and Factor VIII into circulation. Plasma vWF rises 2–5 fold within 30–60 minutes, and the released HMW multimers dramatically enhance platelet adhesion to damaged vascular surfaces by bridging the platelet GPIb-IX-V receptor complex to exposed subendothelial collagen. This dual mechanism — amplified platelet adhesion and elevated FVIII — is why DDAVP is already a first-line treatment for mild hemophilia A and vWD type 1.

The strongest repurposing case in this dataset is for primary release disorder of platelets (Rank 4). Patients with delta-storage pool disease, aspirin-like cyclooxygenase defects, or α-granule ADP/serotonin insufficiency have platelets that adhere normally but fail to release granule contents after activation, impairing secondary platelet plug consolidation. Desmopressin’s burst of HMW vWF multimers strengthens the upstream, granule-independent adhesion pathway (GPIb-vWF axis), partially compensating for the downstream release failure and measurably shortening the bleeding time. This mechanism is directly confirmed in pediatric aspirin-like defect patients (PMID 21509710) and in a broader platelet dysfunction cohort (PMID 1613990), and is endorsed by a 2023 systematic review (PMID 36656570).

For Glanzmann thrombasthenia (Rank 3), the mechanism is weaker but not implausible: GT results from deficient or dysfunctional GPIIb/IIIa (αIIbβ3 integrin), abolishing platelet aggregation but leaving GPIb-mediated adhesion intact. Desmopressin, by boosting HMW vWF, can enhance GPIb-dependent adhesion as a partial compensatory route. Multiple management guidelines include DDAVP as a secondary adjunct for mild bleeding in GT, though no RCT has been conducted. In contrast, the high TxGNN scores for congenital prothrombin deficiency (Rank 1) and inherited thrombophilia (Rank 2) appear to reflect broad knowledge graph proximity within a “bleeding/coagulation disorder” cluster rather than true drug-disease mechanistic relevance: Factor II deficiency operates through the extrinsic/common coagulation pathway that DDAVP cannot correct, and inherited thrombophilia is a hypercoagulable state where Desmopressin’s pro-adhesion, pro-coagulant properties could actively precipitate thrombotic events — a risk documented in the literature (PMID 16460464).

Clinical Trial Evidence

Only one clinical trial was retrieved across all 7 predicted indications. It has been assessed as Grade C (not relevant): the trial drug is Emicizumab, not Desmopressin, and the target population is mild hemophilia A, not any of the 7 predicted indications.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04567511	Phase 4	Recruiting	20	Emicizumab in mild hemophilia A (FVIII 5–30%), evaluating coagulation parameters, joint health, and quality of life. The trial drug is Emicizumab, not Desmopressin; the disease is mild hemophilia A, not congenital prothrombin deficiency. This appears to be a knowledge graph retrieval error and provides no evidence for this drug-disease pair.

No registered clinical trials were found evaluating Desmopressin in any of the 7 predicted indications.

Literature Evidence

Literature was retrieved for all 7 indications. The tables below prioritize the two most actionable predictions.

Rank 4: Primary Release Disorder of Platelets — Proceed with Guardrails

PMID	Year	Type	Journal	Key Findings
36656570	2023	Systematic Review	Eur J Haematol	Confirms DDAVP efficacy in platelet function disorders; also active in mild hemophilia A, vWD, uremia, and liver disease. Flags hyponatremia and rare arterial thrombosis as complications.
21509710	2011	Clinical Observational Study	Klin Padiatr	Direct evaluation of DDAVP on primary hemostasis in pediatric patients with aspirin-like defect (hereditary thrombocytopathy); documents shortening of bleeding time via whole-blood platelet function diagnostics.
23051555	2013	Mechanistic Clinical Study	Haemophilia	DDAVP increases VWF bound to platelet-derived microparticles, suggesting a VWF/FVIII-independent hemostatic mechanism relevant to platelet release disorders.
30986390	2019	Clinical Practice Guideline	Gastroenterology	AGA guideline on coagulation in cirrhosis; contextualizes DDAVP use in settings of mixed platelet and hemostatic dysfunction.
1613990	1992	Clinical Study	Nihon Rinsho	Japanese study of DDAVP in 11 patients with platelet dysfunction including release defects; demonstrates bleeding time shortening and evidence for bypassing the granule release step.
22726100	2012	Review	Haemophilia	Comprehensive review of inherited platelet disorders; discusses DDAVP as an adjunct option for storage pool diseases and release defects including delta-SPD.
18278172	2008	Review	Thromb Haemost	Reviews congenital platelet dysfunction; identifies vWF-GPIb axis as a potential compensatory target when platelet granule release is impaired.
7819105	1994	Clinical Study	Br J Haematol	High-shear platelet aggregation (vWF-dependent) in a congenital ADP receptor defect patient; supports the rationale for vWF-mediated compensation in ADP-release disorders.

Rank 3: Glanzmann Thrombasthenia — Research Question

PMID	Year	Type	Journal	Key Findings
10509036	1999	Clinical Study	Haematologica	Direct in vitro and in vivo assessment of DDAVP on platelet function; demonstrates partial hemostatic benefit via pathways independent of GPIIb/IIIa in GT patients.
19967146	2009	Clinical Guideline / Consensus	Thromb Haemost	Expert consensus on GT management; lists DDAVP as an adjunct option for mild bleeding or surgical prophylaxis, prior to platelet transfusion.
22726101	2012	Review / Guideline	Haemophilia	Treatment guideline for inherited platelet disorders; notes DDAVP as a potential adjunct to reduce platelet transfusion requirements in GT.
16444446	2006	Case Report	Clin Appl Thromb Hemost	GT patient undergoing dental extraction: DDAVP alone was insufficient, but rFVIIa administered after DDAVP achieved adequate hemostasis — defines DDAVP’s role as an adjunct, not monotherapy.
1785670	1991	Clinical Study	Am J Pediatr Hematol Oncol	DDAVP + ethamsylate in 12 patients with marked bleeding time prolongation including 1 GT patient; synergistic bleeding time shortening observed in combined administration.

Philippines Market Information

Desmopressin is not currently registered with the Food and Drug Administration (FDA) of the Philippines. No product authorizations were identified.

Item	Detail
Total FDA Philippines Registrations	0
Market Status	Not marketed
Available Routes of Administration	None (local data)
International Reference	Available in other markets as DDAVP (Sanofi), Minirin (Ferring), and Stimate; formulations include intranasal spray, IV injection, oral tablets, and sublingual tablets
Access Pathway	Import registration or compassionate use application would be required for Philippines patient access

Safety Considerations

Formal package insert warnings and contraindications were not retrieved in this evidence pack. The following safety signals are derived from the collected literature and are critical for clinical decision-making:

Hyponatremia: Desmopressin activates V2 receptors in the renal collecting duct, increasing water reabsorption and diluting serum sodium. Risk is highest in children, elderly patients, and those with excessive fluid intake. Serum sodium monitoring is mandatory with any DDAVP dosing regimen (PMID 36656570).
Contraindication in Pseudo-von Willebrand Disease (Rank 5): Platelet-type VWD (PT-VWD) involves GPIbα gain-of-function mutations causing excessive binding affinity for HMW vWF multimers. Desmopressin releases exactly these multimers, potentially triggering paradoxical platelet consumption, thrombocytopenia worsening, and increased bleeding risk. This is a mechanistic contraindication supported by case series evidence (PMID 27819553).
Risk of Thrombosis in Thrombophilic Conditions (Rank 2): DDAVP’s pro-coagulant and pro-adhesion actions are inherently dangerous in hypercoagulable states. PMID 16460464 documents TTP exacerbation following DDAVP administration in a patient with inherited thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Use in patients with Factor V Leiden, prothrombin G20210A, or Protein C/S deficiency should be avoided or approached only with specialist oversight.
Tachyphylaxis: Repeated DDAVP dosing depletes endothelial vWF stores; hemostatic efficacy diminishes markedly with doses given within 24–48 hours of each other. Spacing requirements must be built into any treatment protocol.
Arterial Thrombotic Events: Rare cases of myocardial infarction and stroke have been reported, particularly in elderly patients or those with pre-existing cardiovascular disease (PMID 36656570).

Conclusion and Next Steps

This multi-indication evaluation yields tiered recommendations. The actionable finding is confined to Rank 4; the remaining predictions require either a hold or further research justification.

Rank 4: Primary Release Disorder of Platelets

Decision: Proceed with Guardrails

Rationale: A 2023 systematic review (PMID 36656570) and multiple clinical observational studies confirm that Desmopressin shortens bleeding time in inherited platelet release disorders by augmenting GPIb-mediated adhesion as a compensatory mechanism — a plausible, clinically documented pathway that supports proceeding to a structured feasibility evaluation.

To proceed, the following is needed:

Retrieve full DrugBank MOA profile and package insert safety data to close data gaps DG001 and DG002
Identify patients with confirmed platelet release disorder diagnoses (delta-SPD or aspirin-like defect) via specialist haematology referral
Design a supervised DDAVP challenge protocol with pre/post bleeding time measurement to establish individual patient response
Implement serum sodium monitoring (baseline + 4–8 hours post-dose) in all trial patients
Pursue Philippines FDA registration or compassionate use pathway before clinical use

Rank 3: Glanzmann Thrombasthenia

Decision: Research Question

Rationale: Multiple haematology guidelines acknowledge DDAVP as a secondary adjunct in GT for mild bleeding or peri-procedural prophylaxis, but the evidence base is limited to observational studies, case reports, and expert consensus. No RCT exists. A prospectively designed case series or n-of-1 trial design through an international rare disease registry would be the appropriate next step.

To proceed, the following is needed:

Systematic literature review specifically evaluating DDAVP adjunct versus platelet transfusion alone in GT
Collaboration with international GT registries (e.g., Platelet Immunology Workshop, EUHANET)
Pre-specified hemostatic response endpoints (bleeding time, ROTEM/TEG parameters, clinical hemostasis)

Ranks 1, 6, and 7: Congenital Prothrombin Deficiency / Scott Syndrome / Flood Factor Deficiency

Decision: Hold

Rationale:

Rank 1 (Congenital prothrombin deficiency): Desmopressin has no mechanism to correct Factor II deficiency. The high TxGNN score reflects knowledge graph node proximity within a broad bleeding disorder cluster, not a genuine drug-disease mechanistic link. The only retrieved trial was for an entirely different drug (Emicizumab). No further evaluation is warranted.
Rank 6 (Scott syndrome): The defect in TMEM16F (phospholipid scramblase) preventing phosphatidylserine membrane exposure has no mechanistic intersection with the vWF/FVIII axis. DDAVP cannot compensate for absent procoagulant phospholipid surface. Only one peripheral review paper was retrieved; no direct DDAVP evidence exists.
Rank 7 (Flood factor deficiency): This is not a recognized disease entity in ICD-11, OMIM, or OrphaNet. The term likely reflects a knowledge graph alignment error — possibly a typographical variant of “blood/coagulation factor deficiency.” The sole retrieved literature concerns von Willebrand disease. The disease entity must be clarified before any evaluation can proceed; if the intended target is vWD type 1, Desmopressin already holds established approval for that indication elsewhere.

Rank 2: Inherited Thrombophilia

Decision: Hold — Active Safety Concern

Rationale: Desmopressin’s pro-coagulant mechanism is directly counterproductive in hypercoagulable states. Literature documents TTP exacerbation following DDAVP in inherited thrombotic thrombocytopenic purpura (PMID 16460464). This prediction reflects a serious mechanistic contradiction and should not be pursued.

Rank 5: Pseudo-von Willebrand Disease

Decision: Hold — Potential Contraindication

Rationale: Desmopressin’s release of HMW vWF multimers directly triggers excessive platelet consumption through the pathologically overactive GPIbα receptor in PT-VWD. This creates a paradoxical worsening of thrombocytopenia and bleeding — the opposite of the intended therapeutic effect. Clinical literature supports treating this as a contraindication until prospective safety data demonstrate otherwise.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.